Drug Trial Radar · NCT07659574
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone(UNIGUIDE-1)
Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
360
Planned (sponsor's estimate)
Start
Sep 7, 2026
Primary completion
Sep 24, 2027
Study completion Oct 22, 2027
Sponsor
- Lead sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multicenter, randomized, double-Blind, parallel-group, placebo-controlled phase III trial is to evaluate the efficacy and safety of UBT251 Injection in patients with Type 2 Diabetes Mellitus with inadequate glycemic control on diet and exercise alone
Conditions
- Type 2 Diabetes
Interventions
UBT251 Injection 2.0 mgDrug
UBT251 Injection subcutaneously once weekly
UBT251 Injection 4.0 mgDrug
UBT251 Injection subcutaneously once weekly
UBT251 Injection 6.0 mgDrug
UBT251 Injection subcutaneously once weekly
UBT251 Injection Placebo 2.0 mgDrug
UBT251 Injection placebo subcutaneously once weekly
UBT251 Injection Placebo 4.0 mgDrug
UBT251 Injection placebo subcutaneously once weekly
UBT251 Injection Placebo 6.0 mgDrug
UBT251 Injection placebo subcutaneously once weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- HbA1cTime frame: Week 40
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.